$3.86
-5.9%Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
Chief Executive Officer & Director
Compensation
$854,212
Chief Financial Officer
Compensation
$462,001
Chief Human Resources Officer
Chief Medical Officer & Head of Development
Compensation
$597,411
Chief Operating Officer, Chief Legal Officer & Corporate Secretary
Compensation
$653,839
Chief Technology Officer
Founder & Director
Compensation
$1,011,553
During the last 12 months, insiders have purchased $13.37M worth of ZURA shares, with no selling activity reported.
0
0.00
0
0.00
+0
+$0
2.0M
12.50M
0
0.00
+12.5M
+$12.50M
0
0.00
0
0.00
+0
+$0
672.0K
873.60K
0
0.00
+874K
+$874K
Ai Biotechnology Llc
10 Percent Owner
$12.50M
Hyllengren Eric J
Officer: Chief Financial Officer
$874K
No selling activity
Strong bullish signal with $13.37M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
2 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
ZURA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 17, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 23, 2025 | May 21, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | September 13, 2024 | October 23, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | May 19, 2023 | June 01, 2023 | 2023 | |
DEF 14A DEF 14A 2023 N/A | December 06, 2022 | January 12, 2023 | 2023 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.